This company has been acquired
JNCE Stock Overview
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Jounce Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$5.49 |
| 52 Week Low | US$0.58 |
| Beta | 0.75 |
| 1 Month Change | -0.53% |
| 3 Month Change | 55.37% |
| 1 Year Change | -65.76% |
| 3 Year Change | -60.34% |
| 5 Year Change | -88.80% |
| Change since IPO | -89.10% |
Recent News & Updates
Recent updates
We're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Rate
Jan 04
Here's Why We're Watching Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Sep 20Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Jun 16We Think Jounce Therapeutics (NASDAQ:JNCE) Can Easily Afford To Drive Business Growth
Feb 23Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 Catalysts
Dec 16News Flash: Analysts Just Made A Dazzling Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Aug 07Jounce Therapeutics: An Under The Radar And Undervalued Biotech
Jul 13Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) Revenues
Jun 16Shareholders May Not Be So Generous With Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation And Here's Why
Jun 12Jounce Therapeutics EPS beats by $0.01, misses on revenue
May 04We're Hopeful That Jounce Therapeutics (NASDAQ:JNCE) Will Use Its Cash Wisely
May 03Jounce Therapeutics (NASDAQ:JNCE) Shareholders Have Enjoyed An Impressive 163% Share Price Gain
Mar 02News Flash: Analysts Just Made A Sizeable Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Mar 02Enrollment underway in Jounce Therapeutics' early-stage JTX-8064 study in solid tumors
Jan 13Have Insiders Sold Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Recently?
Jan 13
Jounce Therapeutics: A Potential Roller Coaster
Dec 31A Look At Jounce Therapeutics' (NASDAQ:JNCE) CEO Remuneration
Dec 15Shareholder Returns
| JNCE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.6% | -4.7% | -3.7% |
| 1Y | -65.8% | -2.7% | 20.2% |
Return vs Industry: JNCE underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: JNCE underperformed the US Market which returned -1.4% over the past year.
Price Volatility
| JNCE volatility | |
|---|---|
| JNCE Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: JNCE's share price has been volatile over the past 3 months.
Volatility Over Time: JNCE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 141 | n/a | jouncetx.com |
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy.
Jounce Therapeutics, Inc. Fundamentals Summary
| JNCE fundamental statistics | |
|---|---|
| Market cap | US$98.96m |
| Earnings (TTM) | -US$50.92m |
| Revenue (TTM) | US$82.00m |
1.2x
P/S Ratio-1.9x
P/E RatioIs JNCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNCE income statement (TTM) | |
|---|---|
| Revenue | US$82.00m |
| Cost of Revenue | US$54.80m |
| Gross Profit | US$27.20m |
| Other Expenses | US$78.12m |
| Earnings | -US$50.92m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 33.17% |
| Net Profit Margin | -62.10% |
| Debt/Equity Ratio | 0% |
How did JNCE perform over the long term?
See historical performance and comparison